Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development

Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development
Business Wire - 3 minutes ago
ALBANY, NY--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) announced today that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company (NYSE: BMY) will ...